MCID: HMG002
MIFTS: 52

Hemoglobinuria

Categories: Immune diseases, Blood diseases, Nephrological diseases

Aliases & Classifications for Hemoglobinuria

Summaries for Hemoglobinuria

MalaCards based summary : Hemoglobinuria is related to aplastic anemia and paroxysmal nocturnal hemoglobinuria, and has symptoms including other and unspecified genitourinary symptoms and chyluria. An important gene associated with Hemoglobinuria is PIGA (Phosphatidylinositol Glycan Anchor Biosynthesis Class A), and among its related pathways/superpathways are Innate Immune System and Toxoplasmosis. The drugs Cyclophosphamide and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotype is hematopoietic system.

Wikipedia : 72 In medicine, hemoglobinuria or haemoglobinuria is a condition in which the oxygen transport protein... more...

Related Diseases for Hemoglobinuria

Diseases related to Hemoglobinuria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
# Related Disease Score Top Affiliating Genes
1 aplastic anemia 32.0 CD55 CD59 PIGA
2 paroxysmal nocturnal hemoglobinuria 31.2 C5 CD14 CD55 CD58 CD59 FCGR3B
3 hemolytic anemia 30.2 CD59 HP PIGA
4 anemia, autoimmune hemolytic 29.5 C3 CD55 CD59 HP
5 malaria 28.2 CD55 CR1 HP PLAUR
6 paroxysmal cold hemoglobinuria 12.4
7 paroxysmal nocturnal hemoglobinuria 1 12.3
8 paroxysmal nocturnal hemoglobinuria 2 12.2
9 blackwater fever 11.2
10 blood group, globoside system 10.9
11 warm antibody hemolytic anemia 10.9
12 multiple congenital anomalies-hypotonia-seizures syndrome 10.4 PIGA PIGT
13 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.4
14 complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 10.3
15 thrombosis 10.3
16 acute hemorrhagic conjunctivitis 10.3 C5 CD55
17 dense deposit disease 10.2 C3 C5
18 multiple congenital anomalies-hypotonia-seizures syndrome 2 10.2 CD55 CD59 PIGA
19 acquired angioedema 10.2 C3 HP
20 budd-chiari syndrome 10.2
21 multiple congenital anomalies-hypotonia-seizures syndrome 3 10.2 CD55 CD59 PIGT
22 leukemia 10.2
23 autoimmune disease of blood 10.2 C3 HP
24 complement deficiency 10.1 C3 C5
25 myelodysplastic syndrome 10.1
26 hemoglobinemia 10.1
27 cerebritis 10.1
28 thrombocytopenia 10.1
29 complement factor i deficiency 10.0 C3 CR1
30 thrombophilia due to thrombin defect 10.0
31 hematopoietic stem cell transplantation 10.0
32 proliferative glomerulonephritis 9.9 C3 CR1
33 purpura 9.9
34 hepatitis 9.9
35 lymphoma 9.9
36 retinitis 9.9
37 heparin-induced thrombocytopenia 9.9
38 dirofilariasis 9.9 HP MB
39 blood group, i system 9.9
40 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
41 neutropenia 9.9
42 hemosiderosis 9.9
43 myelofibrosis 9.8
44 myeloma, multiple 9.8
45 aging 9.8
46 pancytopenia 9.8
47 myeloid leukemia 9.8
48 fasciitis 9.8
49 inherited bone marrow failure syndromes 9.8
50 leukemia, chronic lymphocytic 2 9.7

Graphical network of the top 20 diseases related to Hemoglobinuria:



Diseases related to Hemoglobinuria

Symptoms & Phenotypes for Hemoglobinuria

UMLS symptoms related to Hemoglobinuria:


other and unspecified genitourinary symptoms, chyluria

MGI Mouse Phenotypes related to Hemoglobinuria:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.28 C3 CD14 CD55 CD59 FCGR3B HP

Drugs & Therapeutics for Hemoglobinuria

Drugs for Hemoglobinuria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 50-18-0, 6055-19-2 2907
2
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
3
Fludarabine Approved Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
4
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
5
Iodine Approved, Investigational Phase 3 7553-56-2 807
6 Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
7 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
8 Cyclosporins Phase 3,Phase 2,Phase 1
9 Antilymphocyte Serum Phase 3,Phase 2
10 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
11 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
12 Muromonab-CD3 Phase 3,Phase 2
13 Complement Inactivating Agents Phase 3,Phase 1,Phase 2
14 Complement System Proteins Phase 3,Phase 2,Phase 1
15 Immunoglobulins Phase 3,Phase 2
16 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antibodies Phase 3,Phase 2
19
Melphalan Approved Phase 2,Phase 1,Early Phase 1 148-82-3 460612 4053
20
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
21
Nandrolone decanoate Approved, Illicit Phase 1, Phase 2 360-70-3 9677
22
Nandrolone Approved, Experimental, Illicit, Investigational Phase 1, Phase 2 62-90-8, 434-22-0 9904 229455
23
alemtuzumab Approved, Investigational Phase 2,Phase 1,Early Phase 1 216503-57-0
24
Lenograstim Approved, Investigational Phase 2 135968-09-1
25
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
26
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
27
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
28
Vidarabine Approved, Investigational Phase 1, Phase 2, Early Phase 1 24356-66-9 21704 32326
29
Busulfan Approved, Investigational Phase 2,Early Phase 1 55-98-1 2478
30
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
31
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
32
Basiliximab Approved, Investigational Phase 2 179045-86-4, 152923-56-3
33
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
34
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
35
Etoposide Approved Phase 2 33419-42-0 36462
36
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
37
Mesna Approved, Investigational Phase 2 3375-50-6 598
38
Everolimus Approved Phase 2 159351-69-6 6442177
39
Abatacept Approved Phase 1, Phase 2 332348-12-6 10237
40
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
41
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
42
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
43 tannic acid Approved, Nutraceutical Phase 2
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
45
Treosulfan Investigational Phase 2 299-75-2 9296
46 decanoic acid Phase 1, Phase 2
47 glucocorticoids Phase 2
48 Adjuvants, Immunologic Phase 2,Phase 1
49 Anabolic Agents Phase 1, Phase 2
50 Androgens Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 103)

# Name Status NCT ID Phase Drugs
1 Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects Completed NCT00867932 Phase 4 Eculizumab
2 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Unknown status NCT02393508 Phase 3
3 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00098280 Phase 3 Eculizumab
4 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00130000 Phase 3 Eculizumab
5 Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT00122317 Phase 3 eculizumab
6 Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT00112983 Phase 3
7 Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Completed NCT00122330 Phase 3 eculizumab
8 Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Completed NCT00122304 Phase 3 eculizumab
9 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
10 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
11 Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
12 ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Active, not recruiting NCT03056040 Phase 3
13 ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT02946463 Phase 3
14 A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not yet recruiting NCT03406507 Phase 3
15 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
16 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
17 An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Unknown status NCT01579838 Phase 1, Phase 2 Eculizumab
18 Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Unknown status NCT01757145 Phase 2 Eltrombopag
19 Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure Unknown status NCT00895739 Phase 2 cyclosporine
20 Nandrolone Decanoate in the Treatment of Telomeropathies Unknown status NCT02055456 Phase 1, Phase 2 Nandrolone Decanoate
21 E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01194804 Phase 2 Eculizumab
22 C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01192399 Phase 2
23 A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH Completed NCT02352493 Phase 1, Phase 2 ALN-CC5;Sterile Normal Saline (0.9% NaCl)
24 Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA
25 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed NCT00975975 Phase 2 Basiliximab
26 Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome Completed NCT00731328 Phase 2
27 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed NCT01187017 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
28 Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Completed NCT00618969 Phase 2
29 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
30 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
31 Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Completed NCT00997386 Phase 2 busulfan, and melphalan, and alemtuzumab
32 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2 Systematic chemotherapy and antibodies
33 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Completed NCT00145613 Phase 2 Systemic chemotherapy and antibodies
34 Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases Completed NCT02277639 Phase 2
35 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
36 A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03053102 Phase 2 ACH-0144471
37 Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria Recruiting NCT03157635 Phase 1, Phase 2 RO7112689;Placebo
38 Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria Recruiting NCT02534909 Phase 2
39 A Long-term Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03181633 Phase 2 ACH-0144471
40 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
41 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Recruiting NCT01174108 Phase 2
42 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Recruiting NCT00003838 Phase 2
43 Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Recruiting NCT02224872 Phase 2 Thymoglobulin;Fludarabine;Cyclophosphamide;Mesna;Tacrolimus;Mycophenolic acid mofetil
44 Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases Recruiting NCT02349906 Phase 2 Treosulfan;Busilvex
45 Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders Recruiting NCT03128996 Phase 1, Phase 2 RIC regimen;GVHD prophylaxis regimen
46 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
47 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Recruiting NCT01962415 Phase 2 Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa
48 Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers Recruiting NCT01597219 Phase 2
49 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) Active, not recruiting NCT02591862 Phase 2 Coversin
50 Extension Study of RA101495 for Patients With PNH Who Have Completed a RA101495 Clinical Study Active, not recruiting NCT03225287 Phase 2 RA101495

Search NIH Clinical Center for Hemoglobinuria

Cochrane evidence based reviews: hemoglobinuria

Genetic Tests for Hemoglobinuria

Genetic tests related to Hemoglobinuria:

# Genetic test Affiliating Genes
1 Hemoglobinuria 28

Anatomical Context for Hemoglobinuria

MalaCards organs/tissues related to Hemoglobinuria:

38
Bone, Bone Marrow, T Cells, Kidney, Testes, Myeloid, Neutrophil

Publications for Hemoglobinuria

Articles related to Hemoglobinuria:

(show top 50) (show all 861)
# Title Authors Year
1
Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. ( 29131151 )
2018
2
Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. ( 29383624 )
2018
3
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility. ( 29236352 )
2018
4
Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients. ( 29323198 )
2018
5
Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab. ( 29102415 )
2018
6
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 4 - assay validation and quality assurance. ( 29251828 )
2018
7
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 - reagent selection and assay optimization for high-sensitivity testing. ( 29236353 )
2018
8
Introduction to ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria and related disorders. ( 29389086 )
2018
9
Microangiopathy and acute kidney injury in paroxysmal cold hemoglobinuria: A challenge for management. ( 29341234 )
2018
10
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. ( 29314145 )
2018
11
The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. ( 29246924 )
2018
12
Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. ( 29021487 )
2018
13
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 3 - data analysis, reporting and case studies. ( 29236350 )
2018
14
Acute kidney injury in a postpartum woman with paroxysmal nocturnal hemoglobinuria: A case report and literature review. ( 28796431 )
2017
15
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. ( 27837250 )
2017
16
Paroxysmal Nocturnal Hemoglobinuria Assessment by Flow Cytometric Analysis. ( 29128072 )
2017
17
Paroxysmal Nocturnal Hemoglobinuria in the Differential Diagnosis of Thrombocytopenia. ( 28435653 )
2017
18
Low-dose prednisolone in patients with paroxysmal nocturnal hemoglobinuria and inadequate response to eculizumab. ( 29333418 )
2017
19
Renal Manifestations in Paroxysmal Nocturnal Hemoglobinuria. ( 28761231 )
2017
20
T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways. ( 28630090 )
2017
21
Kids, colds, and complement: paroxysmal cold hemoglobinuria. ( 28594143 )
2017
22
Fluorescent Aerolysin (FLAER)-based paroxysmal nocturnal hemoglobinuria (PNH) screening: a single center experience from India. ( 28432724 )
2017
23
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. ( 28246555 )
2017
24
Polymorphism of the<i>ABO</i>gene associate with thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. ( 29190926 )
2017
25
Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014;123(13):2094-2101. ( 28408428 )
2017
26
Standardized high-sensitivity flow cytometry testing for paroxysmal nocturnal hemoglobinuria in children with acquired bone marrow failure disorders: A single center US study. ( 28574201 )
2017
27
Paroxysmal cold hemoglobinuria: a difficult diagnosis in adult patients. ( 27807852 )
2017
28
Distinct clinical characteristics of paroxysmal nocturnal hemoglobinuria in patients in Southern Taiwan: A multicenter investigation. ( 28811010 )
2017
29
Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. ( 28332730 )
2017
30
Deep sequencing of whole genome exon in paroxysmal nocturnal hemoglobinuria. ( 28124384 )
2017
31
Paroxysmal Nocturnal Hemoglobinuria in Pregnancy: A Dilemma in Treatment and Thromboprophylaxis. ( 29147590 )
2017
32
Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia. ( 28675769 )
2017
33
Paroxysmal nocturnal hemoglobinuria clones are not infrequent in patients with inherited bone marrow failure syndromes. ( 28452421 )
2017
34
Primary Myoglobinuria: Differentiate Myoglobinuria from Hemoglobinuria. ( 28811700 )
2017
35
Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria. ( 28447244 )
2017
36
Pathology of Naturally Occurring Bacillary Hemoglobinuria in Cattle. ( 28438111 )
2017
37
Role of kidney MRI to monitoring clearance of hemosiderin deposits in paroxysmal nocturnal hemoglobinuria. ( 28434706 )
2017
38
Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. ( 28437723 )
2017
39
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry. ( 28748287 )
2017
40
A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients. ( 28380398 )
2017
41
Paroxysmal nocturnal hemoglobinuria with spontaneous clinical remission. ( 28528998 )
2017
42
Acute myeloid leukemia and fatal<i>Scedosporium prolificans</i>sepsis after eculizumab treatment for paroxysmal nocturnal hemoglobinuria: a case report. ( 29359139 )
2017
43
Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report. ( 28328837 )
2017
44
Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. ( 28646725 )
2017
45
Severe Neutropenia After Leukocytosis During an Acute Attack of Mycoplasma Infection-associated Paroxysmal Cold Hemoglobinuria. ( 28234745 )
2017
46
Immune Hemolytic Anemia (Paroxysmal Cold Hemoglobinuria) Preceding Burkitt Lymphoma in a 12-Year-Old Child. ( 27879544 )
2017
47
Renal Biopsy in Paroxysmal Nocturnal Hemoglobinuria: An Insight into the Spectrum of Morphologic Changes. ( 28761230 )
2017
48
Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with Eculizumab: a retrospective study of 21 patients from SFGM-TC centers. ( 29269526 )
2017
49
Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. ( 29043236 )
2017
50
Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants. ( 28692147 )
2017

Variations for Hemoglobinuria

Expression for Hemoglobinuria

Search GEO for disease gene expression data for Hemoglobinuria.

Pathways for Hemoglobinuria

Pathways related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 C3 C5 CD14 CD55 CD58 CD59
2
Show member pathways
11.98 C3 CR1 FCGR3B
3 11.96 C3 CD14 CR1 FCGR3B
4 11.88 C3 CD14 FCGR3B
5
Show member pathways
11.82 C3 C5 CD55 CD59 CR1
6
Show member pathways
11.68 C3 C5 CD55 CD59 CR1
7
Show member pathways
11.66 FCGR3B PIGA PIGT PLAUR
8 11.62 C3 CR1 FCGR3B
9 11.61 CD14 CD55 CD59 CR1
10 11.55 C3 C5 CD14
11 11.38 C3 C5 FCGR3B
12
Show member pathways
11.37 C3 C5 CD55 CD59 CR1
13 11.35 C3 CD14 CR1
14 11.24 C3 C5 CD55 CD59 CR1 PLAUR
15
Show member pathways
11.16 PIGA PIGT

GO Terms for Hemoglobinuria

Cellular components related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 C3 C5 CD14 CD55 CD59 FCGR3B
2 extracellular space GO:0005615 9.91 C3 C5 CD14 CD59 HP SEMA7A
3 extracellular exosome GO:0070062 9.9 C3 C5 CD14 CD55 CD58 CD59
4 cell surface GO:0009986 9.73 CD14 CD55 CD58 CD59 CR1 PLAUR
5 ficolin-1-rich granule membrane GO:0101003 9.5 CD55 CD58 CR1
6 anchored component of external side of plasma membrane GO:0031362 9.4 CD14 CD59
7 secretory granule membrane GO:0030667 9.35 CD14 CD55 CD58 CR1 FCGR3B
8 anchored component of membrane GO:0031225 9.17 CD14 CD55 CD58 CD59 FCGR3B PLAUR

Biological processes related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.77 C3 C5 CD14 CD55 CR1
2 inflammatory response GO:0006954 9.76 C3 C5 CD14 SEMA7A
3 positive regulation of protein phosphorylation GO:0001934 9.65 C3 PLAUR SEMA7A
4 immune system process GO:0002376 9.65 C3 C5 CD14 CD55 CR1
5 GPI anchor biosynthetic process GO:0006506 9.51 PIGA PIGT
6 positive regulation of vascular endothelial growth factor production GO:0010575 9.49 C3 C5
7 complement activation, classical pathway GO:0006958 9.46 C3 C5 CD55 CR1
8 positive regulation of interleukin-8 secretion GO:2000484 9.43 CD14 CD58
9 complement activation, alternative pathway GO:0006957 9.4 C3 C5
10 regulation of complement activation GO:0030449 9.35 C3 C5 CD55 CD59 CR1
11 attachment of GPI anchor to protein GO:0016255 9.32 PIGT PLAUR
12 neutrophil degranulation GO:0043312 9.28 C3 CD14 CD55 CD58 CD59 CR1

Molecular functions related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase inhibitor activity GO:0004866 8.96 C3 C5
2 receptor binding GO:0005102 8.92 C3 C5 CD58 PLAUR

Sources for Hemoglobinuria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....